SOLIGENIX, INC. (SNGX)
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
📈 **POSITIVE** • High confidence analysis (86%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business